Skip to Main content Skip to Navigation
Journal articles

Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1

Abstract : Immune checkpoint inhibitors (ICIs) have dramatically modified the prognosis of several advanced cancers, however many patients still do not respond to treatment. Optimal results might be obtained by targeting cancer cell metabolism to modulate the immunosuppressive tumor microenvironment. Here, we identify sphingosine kinase-1 (SK1) as a key regulator of anti-tumor immunity. Increased expression of SK1 in tumor cells is significantly associated with shorter survival in metastatic melanoma patients treated with anti-PD-1. Targeting SK1 markedly enhances the responses to ICI in murine models of melanoma, breast and colon cancer. Mechanistically, SK1 silencing decreases the expression of various immunosuppressive factors in the tumor microenvironment to limit regulatory T cell (Treg) infiltration. Accordingly, a SK1-dependent immunosuppressive signature is also observed in human melanoma biopsies. Altogether, this study identifies SK1 as a checkpoint lipid kinase that could be targeted to enhance immunotherapy.
Document type :
Journal articles
Complete list of metadata

Cited literature [55 references]  Display  Hide  Download
Contributor : Myriam Bodescot Connect in order to contact the contributor
Submitted on : Wednesday, February 26, 2020 - 5:02:40 PM
Last modification on : Thursday, August 4, 2022 - 4:56:01 PM
Long-term archiving on: : Wednesday, May 27, 2020 - 7:52:11 PM


Publication funded by an institution


Distributed under a Creative Commons Attribution 4.0 International License



Caroline Imbert, Anne Montfort, Marine Fraisse, Elie Marcheteau, Julia Gilhodes, et al.. Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1. Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.437. ⟨10.1038/s41467-019-14218-7⟩. ⟨inserm-02492179⟩



Record views


Files downloads